reference/16754482

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16754482

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	489
issn	0007-0920 1532-1827
issueIdentifier	3
pageRange	482-489
publicationName	British Journal of Cancer
startingPage	482
bibliographicCitation	Coley HM, Safuwan NAM, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, Madhuri K, Lovell DP, Crook T. The cyclin-dependent kinase inhibitor p57Kip2 is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. British Journal of Cancer. 2012 Jan 10;106(3):482–9. doi: 10.1038/bjc.2011.566.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_944dac475681d8f374a3a68c46cc7f31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f1c0053ba979867e0762c4bcf0eedcc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_10b9ca837a6e443b87a197ea924b8c5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7218b4dea4abb6a34d5ecdc77225de1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8b5c84a95895aa19ccd5bf0411e5a40 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4fb35a2c5bf9e1bfe6426cdc4469293 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8590a3f81c3b4c71a8d6f4cde1829d8d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97055d2b1402bafba9e4b19727aa5aea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c09b25ee59f3ffba0e28ab8d3e3773d
date	2012-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/22233925 https://doi.org/10.1038/bjc.2011.566 https://pubmed.ncbi.nlm.nih.gov/PMC3273354
isPartOf	https://portal.issn.org/resource/ISSN/0007-0920 https://portal.issn.org/resource/ISSN/1532-1827 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
language	English
source	https://scigraph.springernature.com/ https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
discusses	http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0203045 http://id.nlm.nih.gov/mesh/M0018169 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0273114
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/11 http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_669a31416f6beea5dd65ab087ad051f9 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3c1afdc4df89db197401645db6998055 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9444 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.11.22 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID160355 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7af7b271b7f5b40158613a3c5521a3fb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d73d50d84fa7f2e576fa6595a19799a6 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18604151 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0d03172548c6bd63b0e3329865e3ade4 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_328e8296d344517ba83ec79414ad8f86 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6653 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_562c8631efeaf61a73a4206ef1b58061

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127565238 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136083897 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1028

Total number of triples: 56.